The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
MicroRNA replacement therapy in cancer
Open accessAbstract
Despite the recent progress in cancer management approaches, the mortality rate of cancer is still growing and there are lots of challenges in the clinics in terms of novel therapeutics. MicroRNAs (miRNA) are regulatory small noncoding RNAs and are already confirmed to have a great role in regulating gene expression level by targeting multiple molecules that affect cell physiology and disease development. Recently, miRNAs have been introduced as promising therapeutic targets for cancer treatment. Regulatory potential of tumor suppressor miRNAs, which enables regulation of entire signaling networks within the cells, makes them an interesting option for developing cancer therapeutics. In this regard, over recent decades, scientists have aimed at developing powerful and safe targeting approaches to restore these suppressive miRNAs in cancerous cells. The present review summarizes the function of miRNAs in tumor development and presents recent findings on how miRNAs have served as therapeutic agents against cancer, with a special focus on tumor suppressor miRNAs (mimics). Moreover, the latest investigations on the therapeutic strategies of miRNA delivery have been presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family
Chen, L., Zhang, S., Wu, J., Cui, J., Zhong, L., Zeng, L., & Ge, S. (2017) · Oncogene · doi:10.1038/onc.2017.89 · Cited by 392
RetractedLi, N., Miao, Y., Shan, Y., Liu, B., Li, Y., Zhao, L., & Jia, L. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.119 · Cited by 188
RetractedKang, L., Mao, J., Tao, Y., Song, B., Ma, W., Lü, Y., Zhao, L., Li, J., Yang, B., & Li, L. (2015) · Cancer Science · doi:10.1111/cas.12656 · Cited by 132
RetractedSecond-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
Gao, S., Wu, Ding, Gao, Wang, Fan, Wang, Zhang, Wang, Ye, et al. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s23747 · Cited by 111
RetractedmicroRNA-130a is an oncomir suppressing the expression of CRMP4 in gastric cancer
Zhou, Y., Li, R., Yu, H., Wang, R., & Shen, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139443 · Cited by 19
RetractedSynthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo
Zhang, Q., Yan, W., Bai, Y., Xu, H., Fu, C., Zheng, W., Zhu, Y., & Ma, J. (2014) · Oncology Reports · doi:10.3892/or.2014.3591 · Cited by 18
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429 · cited 4×
“cancer therapeutic approaches based on miRNAs could be a very attractive way for development of more practical strategies in this respect (Bracken et al., 2014; Selbach et al., 2008; Xiao et al., 2013).”
BackgroundInfluentialBiodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Asymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
Ranade, V. V. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817c941f · Cited by 2,775
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
MicroRNA biogenesis pathways in cancer
Lin, S., & Gregory, R. I. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3932 · Cited by 2,112
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666
MicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis
Akinc, A., Thomas, M., Klibanov, A. M., & Langer, R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.696 · Cited by 1,337
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., & Jones, P. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.020 · Cited by 1,335
Doench, J. G., Petersen, C. P., & Sharp, P. A. (2003) · Genes & Development · doi:10.1101/gad.1064703 · Cited by 1,260
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Dendrimer biocompatibility and toxicity
DUNCAN, R., & IZZO, L. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.019 · Cited by 1,158
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene
Lee, Y. S., & Dutta, A. (2007) · Genes & Development · doi:10.1101/gad.1540407 · Cited by 1,152
miRiad Roles for the miR-17-92 Cluster in Development and Disease
Mendell, J. T. (2008) · Cell · doi:10.1016/j.cell.2008.04.001 · Cited by 1,089
Current status of polymeric gene delivery systems☆
PARK, T., JEONG, J., & KIM, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.03.007 · Cited by 944
Tazawa, H., Tsuchiya, N., Izumiya, M., & Nakagama, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707351104 · Cited by 903
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
p53 represses c-Myc through induction of the tumor suppressor miR-145
Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., Elble, R., Watabe, K., & Mo, Y.-Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808042106 · Cited by 841
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Kunath, K. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00076-2 · Cited by 809
Berrino, F., De Angelis, R., Sant, M., Rosso, S., Lasota, M. B., Coebergh, J. W., & Santaquilani, M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70245-0 · Cited by 807
OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer
Svoronos, A. A., Engelman, D. M., & Slack, F. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0359 · Cited by 791
An unconventional role for miRNA: let-7 activates toll-like receptor 7 and causes neurodegeneration
Lehmann, S. M., Krüger, C., Park, B., Derkow, K., Rosenberger, K., Baumgart, J., Trimbuch, T., Eom, G., Hinz, M., Kaul, D., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3113 · Cited by 786
MicroRNA sponges: Progress and possibilities
Ebert, M. S., & Sharp, P. A. (2010) · RNA · doi:10.1261/rna.2414110 · Cited by 762
microRNAs in cancer management
Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70073-6 · Cited by 734
LNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA
Vester, B., & Wengel, J. (2004) · Biochemistry · doi:10.1021/bi0485732 · Cited by 727
The influence of surface modification on the cytotoxicity of PAMAM dendrimers
Jevprasesphant, R. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00623-3 · Cited by 726
Ota, A., Tagawa, H., Karnan, S., Tsuzuki, S., Karpas, A., Kira, S., Yoshida, Y., & Seto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3773 · Cited by 724
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0655 · Cited by 677
Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjärn, M., Hansen, J. B., Hansen, H. F., Straarup, E. M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1113 · Cited by 672
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
van Vlerken, L. E., Vyas, T. K., & Amiji, M. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9284-6 · Cited by 645
Ceppi, M., Pereira, P. M., Dunand-Sauthier, I., Barras, E., Reith, W., Santos, M. A., & Pierre, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811073106 · Cited by 631
Silencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
let-7 MicroRNA Functions as a Potential Growth Suppressor in Human Colon Cancer Cells
Akao, Y., Nakagawa, Y., & Naoe, T. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.903 · Cited by 619
The let-7 microRNA reduces tumor growth in mouse models of lung cancer
Esquela-Kerscher, A., Trang, P., Wiggins, J. F., Patrawala, L., Cheng, A., Ford, L., Weidhaas, J. B., Brown, D., Bader, A. G., & Slack, F. J. (2008) · Cell Cycle · doi:10.4161/cc.7.6.5834 · Cited by 593
A PEGylated dendritic nanoparticulate carrier of fluorouracil
Bhadra, D., Bhadra, S., Jain, S., & Jain, N. K. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00132-7 · Cited by 544
Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
Biodegradable nanoparticles for cytosolic delivery of therapeutics
VASIR, J., & LABHASETWAR, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.003 · Cited by 526
Anand, S., Majeti, B. K., Acevedo, L. M., Murphy, E. A., Mukthavaram, R., Scheppke, L., Huang, M., Shields, D. J., Lindquist, J. N., Lapinski, P. E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2186 · Cited by 517
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Regression of murine lung tumors by the let-7 microRNA
Trang, P., Medina, P. P., Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Homer, R., Brown, D., Bader, A. G., Weidhaas, J. B., et al. (2010) · Oncogene · doi:10.1038/onc.2009.445 · Cited by 500
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Babar, I. A., Cheng, C. J., Booth, C. J., Liang, X., Weidhaas, J. B., Saltzman, W. M., & Slack, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201516109 · Cited by 497
Regulatory mechanisms of microRNA expression
Gulyaeva, L. F., & Kushlinskiy, N. E. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0893-x · Cited by 464
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Developing MicroRNA Therapeutics
van Rooij, E., Purcell, A. L., & Levin, A. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247916 · Cited by 449
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Role of microRNAs in translation regulation and cancer
Oliveto, S., Mancino, M., Manfrini, N., & Biffo, S. (2017) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v8.i1.45 · Cited by 431
Improved targeting of miRNA with antisense oligonucleotides
Davis, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl183 · Cited by 422
Takeshita, F., Patrawala, L., Osaki, M., Takahashi, R.-U., Yamamoto, Y., Kosaka, N., Kawamata, M., Kelnar, K., Bader, A. G., Brown, D., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.207 · Cited by 420
Chen, D., Sun, Y., Wei, Y., Zhang, P., Rezaeian, A. H., Teruya-Feldstein, J., Gupta, S., Liang, H., Lin, H.-K., Hung, M.-C., et al. (2012) · Nature Medicine · doi:10.1038/nm.2940 · Cited by 413
Overcoming Nonviral Gene Delivery Barriers: Perspective and Future
Jones, C. H., Chen, C.-K., Ravikrishnan, A., Rane, S., & Pfeifer, B. A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400467x · Cited by 410
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation
Zheng, D., Giljohann, D. A., Chen, D. L., Massich, M. D., Wang, X.-Q., Iordanov, H., Mirkin, C. A., & Paller, A. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118425109 · Cited by 409
MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma
Ibrahim, A. F., Weirauch, U., Thomas, M., Grünweller, A., Hartmann, R. K., & Aigner, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4645 · Cited by 400
Evaluation of polyplexes as gene transfer agents
Gebhart, C. L., & Kabanov, A. V. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00357-1 · Cited by 398
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
Ji, Q., Hao, X., Meng, Y., Zhang, M., DeSano, J., Fan, D., & Xu, L. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-266 · Cited by 394
Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish
Xiao, A., Wang, Z., Hu, Y., Wu, Y., Luo, Z., Yang, Z., Zu, Y., Li, W., Huang, P., Tong, X., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt464 · Cited by 392
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501753102 · Cited by 355
He, X.-X., Chang, Y., Meng, F.-Y., Wang, M.-Y., Xie, Q.-H., Tang, F., Li, P.-Y., Song, Y.-H., & Lin, J.-S. (2012) · Oncogene · doi:10.1038/onc.2011.500 · Cited by 339
Minakuchi, Y. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh093 · Cited by 336
Developing therapeutic microRNAs for cancer
Bader, A. G., Brown, D., Stoudemire, J., & Lammers, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.79 · Cited by 333
Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate
Flynt, A. S., Li, N., Thatcher, E. J., Solnica-Krezel, L., & Patton, J. G. (2007) · Nature Genetics · doi:10.1038/ng1953 · Cited by 326
Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules
Vigderman, L., & Zubarev, E. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.004 · Cited by 305
Metastamir: The Field of Metastasis-Regulatory microRNA Is Spreading
Hurst, D. R., Edmonds, M. D., & Welch, D. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2111 · Cited by 299
Delivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
Silica-based nanoparticles for biomedical applications
Bitar, A., Ahmad, N. M., Fessi, H., & Elaissari, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.06.014 · Cited by 288
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer
Hu, X., Macdonald, D. M., Huettner, P. C., Feng, Z., El Naqa, I. M., Schwarz, J. K., Mutch, D. G., Grigsby, P. W., Powell, S. N., & Wang, X. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.05.022 · Cited by 275
Detecting microRNA binding and siRNA off-target effects from expression data
van Dongen, S., Abreu-Goodger, C., & Enright, A. J. (2008) · Nature Methods · doi:10.1038/nmeth.1267 · Cited by 273
Liu, Y., Lai, L., Chen, Q., Song, Y., Xu, S., Ma, F., Wang, X., Wang, J., Yu, H., Cao, X., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103505 · Cited by 272
Møller, H. G., Rasmussen, A. P., Andersen, H. H., Johnsen, K. B., Henriksen, M., & Duroux, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8349-7 · Cited by 266
Role of anti-oncomirs miR-143 and -145 in human colorectal tumors
Akao, Y., Nakagawa, Y., Hirata, I., Iio, A., Itoh, T., Kojima, K., Nakashima, R., Kitade, Y., & Naoe, T. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.88 · Cited by 262
Inhibition of microRNA with antisense oligonucleotides
Esau, C. C. (2008) · Methods · doi:10.1016/j.ymeth.2007.11.001 · Cited by 257
Kasinski, A. L., & Slack, F. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2001 · Cited by 242
miRNA sponges: soaking up miRNAs for regulation of gene expression
Bak, R. O., & Mikkelsen, J. G. (2014) · WIREs RNA · doi:10.1002/wrna.1213 · Cited by 241
Hwang, D. W., Son, S., Jang, J., Youn, H., Lee, S., Lee, D., Lee, Y.-S., Jeong, J. M., Kim, W. J., & Lee, D. S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.047 · Cited by 234
Tivnan, A., Orr, W. S., Gubala, V., Nooney, R., Williams, D. E., McDonagh, C., Prenter, S., Harvey, H., Domingo-Fernández, R., Bray, I. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038129 · Cited by 233
miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc
Chen, Z., Zeng, H., Guo, Y., Liu, P., Pan, H., Deng, A., & Hu, J. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-151 · Cited by 230
Ren, Y., Zhou, X., Mei, M., Yuan, X.-B., Han, L., Wang, G.-X., Jia, Z.-F., Xu, P., Pu, P.-Y., & Kang, C.-S. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-27 · Cited by 216
Onco‐miR‐155 targets SHIP1 to promote TNFα‐dependent growth of B cell lymphomas
Pedersen, I. M., Otero, D., Kao, E., Miletic, A. V., Hother, C., Ralfkiaer, E., Rickert, R. C., Gronbaek, K., & David, M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900028 · Cited by 209
Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2010) · The Prostate · doi:10.1002/pros.21185 · Cited by 205
microRNA Replacement Therapy for Cancer
Henry, J. C., Azevedo-Pouly, A., & Schmittgen, T. D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0548-9 · Cited by 197
Gardner, M. B., Henderson, B. E., Officer, J. E., Rongey, R. W., Parker, J. C., Oliver, C., Estes, J. D., & Huebner, R. J. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.4.1243 · Cited by 197
MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer
Ouyang, M., Li, Y., Ye, S., Ma, J., Lu, L., Lv, W., Chang, G., Li, X., Li, Q., Wang, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096228 · Cited by 195
Xu, L.-F., Wu, Z.-P., Chen, Y., Zhu, Q.-S., Hamidi, S., & Navab, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103698 · Cited by 194
Wu, Z., Wu, Q., Wang, C., Wang, X., Huang, J., Zhao, J., Mao, S., Zhang, G., Xu, X., & Zhang, N. (2011) · Cancer · doi:10.1002/cncr.25860 · Cited by 192
Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer
ABUE, M., YOKOYAMA, M., SHIBUYA, R., TAMAI, K., YAMAGUCHI, K., SATO, I., TANAKA, N., HAMADA, S., SHIMOSEGAWA, T., SUGAMURA, K., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2014.2743 · Cited by 191
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Pichler, M., & Calin, G. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.253 · Cited by 191
Lu, F., Weidmer, A., Liu, C.-G., Volinia, S., Croce, C. M., & Lieberman, P. M. (2008) · Journal of Virology · doi:10.1128/jvi.00752-08 · Cited by 190
Fu, X., Tian, J., Zhang, L., Chen, Y., & Hao, Q. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.006 · Cited by 187
MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10
Sun, L., Yan, W., Wang, Y., Sun, G., Luo, H., Zhang, J., Wang, X., You, Y., Yang, Z., & Liu, N. (2011) · Brain Research · doi:10.1016/j.brainres.2011.03.013 · Cited by 181
Role of miR-10b in breast cancer metastasis
Ma, L. (2010) · Breast Cancer Research · doi:10.1186/bcr2720 · Cited by 178
Ren, Y., Kang, C.-S., Yuan, X.-B., Zhou, X., Xu, P., Han, L., Wang, G. X., Jia, Z., Zhong, Y., Yu, S., et al. (2010) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856209x415828 · Cited by 175
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
Hsu, S.-H., Yu, B., Wang, X., Lu, Y., Schmidt, C. R., Lee, R. J., Lee, L. J., Jacob, S. T., & Ghoshal, K. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.05.007 · Cited by 173
Su, R., Lin, H.-S., Zhang, X.-H., Yin, X.-L., Ning, H.-M., Liu, B., Zhai, P.-F., Gong, J.-N., Shen, C., Song, L., et al. (2015) · Oncogene · doi:10.1038/onc.2014.274 · Cited by 173
A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells
Ghosh, R., Singh, L. C., Shohet, J. M., & Gunaratne, P. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.023 · Cited by 172
MicroRNA Delivery by Cationic Lipoplexes for Lung Cancer Therapy
Wu, Y., Crawford, M., Yu, B., Mao, Y., Nana-Sinkam, S. P., & Lee, L. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2002076 · Cited by 172
Formulation of poly(d,l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery
Tinsley-Bown, A. M., Fretwell, R., Dowsett, A. B., Davis, S. L., & Farrar, G. H. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00275-8 · Cited by 166
Xie, J., Xie, Q., Zhang, H., Ameres, S. L., Hung, J.-H., Su, Q., He, R., Mu, X., Seher Ahmed, S., Park, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.279 · Cited by 166
Cao, M.-X., Jiang, Y.-P., Tang, Y.-L., & Liang, X.-H. (2017) · Oncotarget · doi:10.18632/oncotarget.13957 · Cited by 165
miR-21 and miR-145 cooperation in regulation of colon cancer stem cells
Yu, Y., Nangia-Makker, P., Farhana, L., G. Rajendra, S., Levi, E., & Majumdar, A. P. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0372-7 · Cited by 163
Torrisani, J., Bournet, B., du Rieu, M. C., Bouisson, M., Souque, A., Escourrou, J. R., Buscail, L., & Cordelier, P. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.134 · Cited by 160
Targeted Delivery Systems for Oligonucleotide Therapeutics
Yu, B., Zhao, X., Lee, L. J., & Lee, R. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9096-1 · Cited by 158
Anson, D. S. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-9 · Cited by 154
RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21
Lee, T. J., Yoo, J. Y., Shu, D., Li, H., Zhang, J., Yu, J.-G., Jaime‐Ramirez, A. C., Acunzo, M., Romano, G., Cui, R., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.016 · Cited by 151
Stahlhut, C. E., & Slack, F. J. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1003008 · Cited by 148
Chiou, G., Cherng, J., Hsu, H., Wang, M., Tsai, C., Lu, K., Chien, Y., Hung, S., Chen, Y., Wong, C.-I., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.014 · Cited by 146
Epigenetic Modification of CCAAT/Enhancer Binding Protein α Expression in Acute Myeloid Leukemia
Hackanson, B. W., Bennett, K. L., Brena, R. M., Jiang, J., Claus, R., Chen, S., Blagitko-Dorfs, N., Maharry, K., Whitman, S. P., Schmittgen, T. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0483 · Cited by 143
MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target
Mellis, D. J., & Caporali, A. (2017) · Biochemical Society Transactions · doi:10.1042/bst20170037 · Cited by 143
Biomaterials for Gene Delivery Atelocollagen-mediated Controlled Release of Molecular Medicines
Ochiya, T., Nagahara, S., Sano, A., Itoh, H., & Terada, M. (2001) · Current Gene Therapy · doi:10.2174/1566523013348887 · Cited by 142
Genome‐wide identification of miR‐200 targets reveals a regulatory network controlling cell invasion
Bracken, C. P., Li, X., Wright, J. A., Lawrence, D., Pillman, K. A., Salmanidis, M., Anderson, M. A., Dredge, B. K., Gregory, P. A., Tsykin, A., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201488641 · Cited by 139
miRNAs and long noncoding RNAs as biomarkers in human diseases
Roosbroeck, K. V., Pollet, J. B. K., & Călin, G. A. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.134 · Cited by 137
Maintaining the silence: reflections on long-term RNAi
Raemdonck, K., Vandenbroucke, R. E., Demeester, J., Sanders, N. N., & Smedt, S. C. D. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.008 · Cited by 124
Dinh, T.-K. T., Fendler, W. M., Chałubińska‐Fendler, J., Acharya, S. S., O’Leary, C., Deraska, P. V., D’Andrea, A. D., Chowdhury, D., & Kozono, D. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0636-4 · Cited by 122
Hu, Q., Jiang, Q., Jin, X., Shen, J., Wang, K., Li, Y. B., Xu, F., Tang, G., & Li, Z. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.016 · Cited by 116
Nanocarriers for microRNA delivery in cancer medicine
Fernandez-Piñeiro, I., Badiola, I., & Sánchez, A. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.03.002 · Cited by 116
Delivery Systems and Local Administration Routes for Therapeutic siRNA
Vicentini, F. T. M. C., Borgheti-Cardoso, L. N., Depieri, L. V., Mano, D. D. M., Abelha, T. F., Petrilli, R., & Bentley, M. V. L. B. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0971-1 · Cited by 115
Cellular Pliancy and the Multistep Process of Tumorigenesis
Puisieux, A., Pommier, R. M., Morel, A., & Lavial, F. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.007 · Cited by 114
Zhou, Y., Zhang, L., Zhao, W., Wu, Y., Zhu, C., & Yang, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.072 · Cited by 113
MicroRNAs as novel players in skin development, homeostasis and disease
Schneider, M. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10568.x · Cited by 110
Liu, X., Song, W., Sun, T., Zhang, P., & Wang, J. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100315q · Cited by 109
Dailey, L. A., Wittmar, M., & Kissel, T. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.003 · Cited by 108
Mirzaei, H., Fathullahzadeh, S., Khanmohammadi, R., Darijani, M., Momeni, F., Masoudifar, A., Goodarzi, M., Mardanshah, O., Stenvang, J., Jaafari, M., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25799 · Cited by 107
Circulating miR-21 as novel biomarker in gastric cancer
Simonian, M., Mosallayi, M., & Mirzaei, H. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.175428 · Cited by 103
Deftereos, G., Corrie, S. R., Feng, Q., Morihara, J. K., Stern, J., Hawes, S. E., & Kiviat, N. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028423 · Cited by 102
MicroRNA as tools and therapeutics in lung cancer
Barger, J. F., & Nana-Sinkam, S. P. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.006 · Cited by 102
MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes
Sachdeva, M., Mito, J. K., Lee, C., Zhang, M., Li, Z., Dodd, R. D., Cason, D., Luo, L., Ma, Y., Mater, D. V., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci77116 · Cited by 99
Ekin, A., Karataş, Ö. F., Çulha, M., & Özen, M. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2810 · Cited by 97
Li, X., Xin, S., He, Z., Che, X., Wang, J., Xiao, X., Chen, J., & Song, X. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000362946 · Cited by 94
Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing
Cheng, C. J., & Saltzman, W. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300081s · Cited by 92
Shi, L., Chen, Z., Wu, L., Zheng, J., Yang, J., Chen, X., Chen, Z.-Q., Cun-li, L., Chi, S.-Y., Zheng, J., et al. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.23.10439 · Cited by 91
MicroRNA Conjugated Gold Nanoparticles and Cell Transfection
Crew, E., Rahman, S., Razzak-Jaffar, A., Mott, D. M., Kamundi, M., Yu, G., Tchah, N., Lee, J., Bellavia, M. C., & Zhong, C. (2011) · Analytical Chemistry · doi:10.1021/ac202749p · Cited by 89
Kasar, S. N., Salerno, E., Yuan, Y., Underbayev, C., Vollenweider, D., Laurindo, M. F. L., Fernandes, H., Bonci, D., Addario, A., Mazzella, F. M., et al. (2011) · Genes and Immunity · doi:10.1038/gene.2011.58 · Cited by 87
Yigit, M., Ghosh, S. K., Kumar, M., Petkova, V., Kavishwar, A., Moore, A., & Medarova, Z. (2012) · Oncogene · doi:10.1038/onc.2012.173 · Cited by 86
Preparation of a Low Molecular Weight Polyethylenimine for Efficient Cell Transfection
Bieber, T., & Elsässer, H. (2001) · BioTechniques · doi:10.2144/01301st03 · Cited by 80
Wang, H., Zhao, X., Guo, C., Ren, D., Zhao, Y., Xiao, W. L., & Jiao, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139136 · Cited by 79
Nedaeinia, R., Sharifi, M., Avan, A., Kazemi, M., Rafiee, L., Ghayour‐Mobarhan, M., & Salehi, R. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.25 · Cited by 78
Snowhite, I. V., Allende, G., Sosenko, J. M., Pastori, R. L., Messinger, S., & Pugliese, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4294-3 · Cited by 78
Teng, Y., Mei, Y., Hawthorn, L., & Cowell, J. (2013) · Oncogene · doi:10.1038/onc.2012.565 · Cited by 77
Guan, Y., Zhang, M., Chen, X., Zhang, Q., Liu, S., & Zhang, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26588 · Cited by 77
Innovative Strategy for MicroRNA Delivery in Human Mesenchymal Stem Cells via Magnetic Nanoparticles
Schade, A., Delyagina, E., Scharfenberg, D., Skorska, A., Lux, C. A., David, R., & Steinhoff, G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140610710 · Cited by 76
Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer
Liu, J. (2009) · Oncology Reports · doi:10.3892/or_00000554 · Cited by 74
Zhao, Z., Ma, X., Sung, D. C., Li, M., Kosti, A., Lin, G. E., Chen, Y., Pertsemlidis, A., Hsiao, T.-H., & Du, L. (2015) · RNA Biology · doi:10.1080/15476286.2015.1023495 · Cited by 73
Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer
Takeyama, H., Yamamoto, H., Yamashita, S., Wu, X., Takahashi, H., Nishimura, J., Haraguchi, N., Miyake, Y., Suzuki, R., Murata, K., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0571 · Cited by 73
Jiang, Y., Tang, G., Zhang, L.-H., Kong, S.-Y., Zhu, S., & Pei, Y. (2010) · Journal of drug targeting · doi:10.3109/10611860903494203 · Cited by 72
Non-coding RNAs: Therapeutic Strategies and Delivery Systems
Ling, H. Y. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42059-2_12 · Cited by 72
Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer
Wen, D., Peng, Y., Feng, L., Singh, R. K., & Mahato, R. I. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2355 · Cited by 67
Shah, P. M., Bristow, M. R., & Port, J. D. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0362-8 · Cited by 65
Kincaid, R. P., Chen, Y., Cox, J. E., Rethwilm, A., & Sullivan, C. S. (2014) · mBio · doi:10.1128/mbio.00074-14 · Cited by 64
The roles of microRNAs in the regulation of tumor metastasis
Zhou, L., Liu, F., Wang, X., & Ouyang, G. (2015) · Cell & Bioscience · doi:10.1186/s13578-015-0028-8 · Cited by 63
Prakash, T. P., Kawasaki, A. M., Wancewicz, E. V., Shen, L., Monia, B. P., Ross, B. S., Bhat, B., & Manoharan, M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701537z · Cited by 63
MicroRNA: master controllers of intracellular signaling pathways
Lui, P., Jin, D., & Stevenson, N. J. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1940-0 · Cited by 62
Cao, M., Deng, X., Su, S., Zhang, F., Xiao, X., Hu, Q., Fu, Y., Yang, B. B., Wu, Y. F., Sheng, W., et al. (2013) · Nanoscale · doi:10.1039/c3nr04056a · Cited by 62
Chung, H. J., Choi, Y. E., Kim, E., Han, Y.-H., Park, M., & Bae, I. H. (2015) · Oncotarget · doi:10.18632/oncotarget.4384 · Cited by 61
Otten, G. R., Schaefer, M. E., Greer, C. E., Calderon-Cacia, M., Coit, D., Kazzaz, J., Medina-Selby, A., Selby, M., Singh, M., Ugozzoli, M., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.10.6087-6092.2003 · Cited by 61
Matamala, N., Vargas, M. T., González‐Cámpora, R., Arias, J. I., Menéndez, P., Andrés‐León, E., Yanowsky, K., Llaneza-Folgueras, A., Miñambres, R., Martínez–Delgado, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7705 · Cited by 59
Deng, X., Liu, Y., Luo, M., Wu, J., Ma, R., Wan, Q., & Wu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18593 · Cited by 58
Bakhshandeh, B., Soleimani, M., Hafizi, M., & Ghaemi, N. (2012) · Cytotechnology · doi:10.1007/s10616-012-9430-9 · Cited by 51
MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells
Yang, L., Li, C., Liang, F., Fan, Y., & Zhang, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.088 · Cited by 50
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment
Zarone, M. R., Misso, G., Grimaldi, A., Zappavigna, S., Russo, M., Amler, E., Martino, M. T. D., Amodio, N., Tagliaferri, P., Tassone, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18186-0 · Cited by 49
ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer
Duhachek-Muggy, S., & Żółkiewska, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1108-1 · Cited by 47
Amodeo, V., Bazan, V., Fanale, D., Insalaco, L., Caruso, S., Cicero, G., Bronte, G., Rolfo, C. D., Santini, D., & Russo, A. D. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.832206 · Cited by 46
Inoue, T., Sugimoto, M., Sakurai, T., Saito, R., Futaki, N., Hashimoto, Y., Honma, Y., Arai, I., & Nakaike, S. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1091 · Cited by 45
A Universal Aptamer Chimera for the Delivery of Functional microRNA-126
Rohde, J.-H., Weigand, J. E., Suess, B., & Dimmeler, S. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0501 · Cited by 44
Wang, K., Chen, X., Zhan, Y., Jiang, W., Liu, X., Wang, X., & Wu, B. (2015) · Tumor Biology · doi:10.1007/s13277-015-3382-6 · Cited by 44
Hatakeyama, H., Murata, M., Sato, Y., Takahashi, M. M., Minakawa, N., Matsuda, A., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.023 · Cited by 44
miR-340 suppresses cell migration and invasion by targeting MYO10 in breast cancer
Chen, C., SUN, Z.-L., Lu, X., Wu, W., Guo, W., Lu, J., Han, C., HUANG, J.-Q., & Fang, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.4411 · Cited by 44
Synthetic Pre-miRNA-Based shRNA as Potent RNAi Triggers
Terasawa, K., Shimizu, K., & Tsujimoto, G. (2011) · Journal of Nucleic Acids · doi:10.4061/2011/131579 · Cited by 42
Li, J., Wang, Z.-L., Xu, W., Li, Q., Gao, L., & Wang, Z. (2016) · Cancer Investigation · doi:10.3109/07357907.2016.1156690 · Cited by 41
Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer
Zhou, B., Xu, H., Xia, M., Sun, C., Li, N., Guo, E., Guo, L., Shan, W., Lu, H., Wu, Y., et al. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0518-7 · Cited by 39
Shi, Y., Cao, T., Huang, H., Lian, C., Yang, Y., Wang, Z., Ma, J., & Xia, J. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1387699 · Cited by 37
Short Double-Stranded RNA with Immunostimulatory Activity: Sequence Dependence
Kabilova, T., Meschaninova, M., Venyaminova, A., Nikolin, V., Zenkova, M., Vlassov, V., & Chernolovskaya, E. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0328 · Cited by 34
Hong, D. S., Kang, Y., Brenner, A. J., Sachdev, J. C., Ejadi, S., Borad, M. J., Kim, T., Lim, H. Y., Park, K., Becerra, C. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2508 · Cited by 34
microRNA-25 promotes osteosarcoma cell proliferation by targeting the cell-cycle inhibitor p27
WANG, X.-H., Cai, P., Wang, M., & Wang, Z. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2260 · Cited by 33
Epigenetic Therapy in Lung Cancer – Role of microRNAs
Rothschild, S. I. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00158 · Cited by 32
Bachetti, T., Zanni, E. D., Ravazzolo, R., & Ceccherini, I. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.06.008 · Cited by 31
Liu, H., Cheng, L., Cao, D., & Zhang, H. (2018) · Medical Science Monitor · doi:10.12659/msm.907038 · Cited by 30
Wu, W., Liu, S., Liang, Y., Zhou, Z., & Liu, X. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0386-x · Cited by 28
Teng, M., Yu, Z., Zhao, P., Zhuang, G., Wu, Z., Lu, D., Li, H., Ma, S.-M., Cui, Z., Zhang, G., et al. (2017) · Journal of General Virology · doi:10.1099/jgv.0.000786 · Cited by 28
Karagonlar, Z. F., Korhan, P., & Atabey, N. (2015) · Drug Development Research · doi:10.1002/ddr.21274 · Cited by 27
Cited by
miRNAs in Cancer (Review of Literature)
Smolarz, B., Durczyński, A., Romanowicz, H., Szyłło, K., & Hogendorf, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052805 · Cited by 296
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
MicroRNAs as regulators of brain function and targets for treatment of epilepsy
Brennan, G. P., & Henshall, D. C. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0369-8 · Cited by 169
Momin, M. Y., Gaddam, R. R., Kravitz, M., Gupta, A., & Vikram, A. (2021) · Cells · doi:10.3390/cells10113097 · Cited by 107
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Metadata
- Authors
- Mollaei, H., Safaralizadeh, R., & Rostami, Z.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2019-01-03
- Volume
- 234
- Issue
- 8
- Pages
- 12369-12384
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2907368400
- Cited by
- 262
- References
- 210
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.